Understanding participation in rhabdomyosarcoma studies
Part of Cancer clinical trials.
This study looks at how people with rhabdomyosarcoma engage with clinical trials, with the goal of improving future trial designs. It does not test a new treatment but collects information that could help improve care for people with this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rhabdomyosarcoma.
- You need to be able to understand and follow the study steps, and be willing to do them.
- You must sign a form to agree to take part, saying you understand the study.
- You cannot be in another clinical trial or have recently been in one.
- If you are pregnant, breastfeeding, or planning to get pregnant during the study, you cannot join.
- You must not have any serious or unstable medical conditions that could complicate the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
This study uses a special machine to find unique protein patterns in rhabdomyosarcoma tumor samples from children and young adults. By analyzing leftover tissue from past biopsies or surgeries, researchers hope to better understand the disease and improve future treatments.
This study tests different treatment plans for children with rhabdomyosarcoma based on their individual risk factors. It aims to find the best therapy for each child, potentially improving outcomes.
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
This trial tests a personalized mRNA vaccine for people with rhabdomyosarcoma that hasn't responded to standard treatments. The vaccine is made to teach your immune system to fight your specific cancer, which might slow or stop the tumor from growing.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.